4.4.5 Cost–effectiveness analysis

While there have been no cost–effectiveness studies looking at the BPaLM regimen, cost–effectiveness studies for the BPaL regimen have demonstrated lower costs, should the regimen be programmatically implemented. Owing to the substantially shorter treatment duration and reduced need for hospitalization (36, 37), the implementation of a national programme using BPaL for MDR/RR-TB was estimated to cost 57–78% less than conventional longer regimens, when including all costs (e.g. investigations, drugs and hospitalization) (36).

Book navigation